Novartis AG (NVS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Novartis Q2 2026 results release conference call and live webcast. Please note that during the presentation, all participants will be in a listen-only mode and the conference is being recorded. After the presentation, there'll be an opportunity to ask questions by pressing star 1 and 1 at any time during the conference. Please limit yourself to one question and return to the queue for any follow-up. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Mr. Nigel Trotman, Head Business Planning and Analysis and Digital Finance. Please go ahead, sir. Thank you, Sharon. Good morning and good afternoon and welcome everyone to our Q2 2026 conference call. The information presented today contains forward-looking statements, that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For description of some of these factors, please refer to the company's Form 20F and its most recent quarterly results on Form 6K that respectively were filed with and furnished to the US Securities and Exchange Commission. Before we get started, and as a reminder, please kindly limit yourselves to one question at a time and we'll cycle through the queue as needed. And with that, I'll hand over to Vaz. Thank you, Nigel. Thanks everyone for joining today's conference call. Moving to slide four, as you saw in the results released earlier today, Novartis delivered strong performance across our priority brands and launches while advancing the pipeline, allowing us to return to growth in the secon...